A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like ...

Federal law allows compounding pharmacies to make copies of name brand drugs while there’s a supply shortage. But there's a ...

New research found hospital visits from Ozempic and Wegovy are rare, but can be serious. Experts explain the finding and ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Novo Nordisk A/S (NYSE:NVO) is the manufacturer and distributor of pharma products, though the company is mainly known for ...

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

As Senators Chris Van Hollen, Cory Booker, and Congresswoman Alexandria Ocasio-Cortez are showing, there is huge political ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government disbursed in foreign aid the same year, according to ForeignAssistance.gov.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...